Overview
- An FDA Pharmacy Compounding Advisory Committee voted last week to allow six largely untested injectable peptides to be added to the list that state‑licensed compounding pharmacies can use, a nonbinding recommendation that does not make the drugs FDA‑approved.
- Career FDA staff scientists and outside clinicians warned the compounds lack robust human trials, have uncertain dosing, and carry risks such as contamination, allergic reactions and possible growth‑related harms like angiogenesis that could theoretically fuel tumors.
- Proponents argue that regulated compounding would replace a risky online gray market that ships research‑grade peptides from overseas, but experts say pharmacy compounding would not substitute for the large clinical trials needed to establish long‑term safety and efficacy.
- Coverage flagged disclosed commercial ties between several panel members and the peptide market and noted the panel dismissed agency staff concerns, raising conflict‑of‑interest questions about the recommendation.
- The FDA will now review the meeting record, public comments and staff analyses before deciding whether to pursue formal rulemaking or other actions, a process officials and stakeholders expect could take months to a year and will shape how widely these peptides are used.